

Author index

Volume 280 (1999)

- Álvarez, V., see Ricós, C. 280, 135
Andersen, P.S., see Larsen, L.A. 280, 113
Andrés, C., see Pudil, R. 280, 127
Arai, K., see Yoshida, K.-i. 280, 195
- Bach, G., Chen, C.-S., Pagano, R.E., Elevated lysosomal pH in Mucopolidosis type IV cells 280, 173
Barange, K., see Miédougé, M. 280, 161
Bates, C.J., Pentieva, K.D., Matthews, N., Macdonald, A., A simple, sensitive and reproducible assay for pyridoxal 5'-phosphate and 4-pyridoxic acid in human plasma 280, 101
Beyer, E.M., Karpova, E.A., Udalova, O.V., Ploos van Amstel, J.K., van Diggelen, O.P., Tsvetkova, I.V., The multiple cases of Fabry disease in a Russian family caused by an E341K amino acid substitution in the α -galactosidase A 280, 81
- Chen, C.-S., see Bach, G. 280, 173
Christiansen, M., see Larsen, L.A. 280, 113
Cole, T.G., see Wu, A.H.B. 280, 181
Contois, J.H., see Wu, A.H.B. 280, 181
- Drahošová, M., see Pudil, R. 280, 127
Drobot, D.W., see Lyon, M.E. 280, 91
- Federspil, G., Vettor, R., Clinical and laboratory logic 280, 25
- Gallo, G., see Kaplan, B. 280, 147
Gregor, J., see Pudil, R. 280, 127
Guidi, G., see Lippi, G. 280, 59
- Haroutunian, V., see Kaplan, B. 280, 147
Hernández, A., see Ricós, C. 280, 135
Honda, M., see Yoshida, K.-i. 280, 195
- Jacobsen, J.R., see Larsen, L.A. 280, 113
Jiménez, C.V., see Ricós, C. 280, 135
Juvany, R., see Ricós, C. 280, 135
- Kanters, J.K., see Larsen, L.A. 280, 113
Kaplan, B., Haroutunian, V., Koudinov, A., Patael, Y., Pras, M., Gallo, G., Biochemical assay for amyloid β deposits to distinguish Alzheimer's disease from other dementias 280, 147
Karpova, E.A., see Beyer, E.M. 280, 81
Kato, N., see Mitsui, T. 280, 205
Kitahara, S., see Yoshida, K.-i. 280, 195
Kondo, T., see Mitsui, T. 280, 205
Koudinov, A., see Kaplan, B. 280, 147
Krejsek, J., see Pudil, R. 280, 127
Larsen, L.A., Andersen, P.S., Kanters, J.K., Jacobsen, J.R., Vuust, J., Christiansen, M., A single strand conformation polymorphism/heteroduplex (SSCP/HD) method for detection of mutations in 15 exons of the *KVLQT1* gene, associated with long QT syndrome 280, 113
Lippi, G., Guidi, G., Biochemical risk factors and patient's outcome: the case of lipoprotein(a) 280, 59
Lundberg, G.D., How clinicians should use the diagnostic laboratory in a changing medical world 280, 3
Lyon, A.W., see Lyon, M.E. 280, 91
Lyon, M.E., Drobot, D.W., Rutledge Harding, S., Lyon, A.W., Evaluation of the thrombin inhibitor D-phenylalanyl-L-prolyl-L-arginine chloromethylketone (PPACK) with the factor Xa inhibitor 1,5-dansyl-L-glutamyl-L-glycyl-L-arginine chloromethylketone (GGACK) as anticoagulants for critical care clinical chemistry specimens 280, 91
Macdonald, A., see Bates, C.J. 280, 101

- Martella, M., see Murigia, A. 280, 73
Matthews, N., see Bates, C.J. 280, 101
Miédougé, M., Salama, G., Barange, K., Vincent, C., Vinel, J.-P., Serre, G., Evaluation of alpha-fetoprotein assay in ascitic fluid for the diagnosis of hepatocellular carcinoma 280, 161
Minchinela, J., see Ricós, C. 280, 135
Mitsui, T., Yuza, N., Kato, N., Kondo, T., Is acetone a normal breath constituent in Japanese? 280, 205
Murigia, A., Polli, R., Martella, M., Vinanzi, C., Opocher, G., Molecular diagnosis of inherited diseases 280, 73

Opocher, G., see Murigia, A. 280, 73

Pagano, R.E., see Bach, G. 280, 173
Pagni, A., Plebani, M., The laboratory and the general practitioner 280, 13
Patael, Y., see Kaplan, B. 280, 147
Pentieva, K.D., see Bates, C.J. 280, 101
Perich, C., see Ricós, C. 280, 135
Pidman, V., see Pudil, R. 280, 127
Plebani, M., The clinical importance of laboratory reasoning 280, 35
Plebani, M., see Pagni, A. 280, 13
Ploos van Amstel, J.K., see Beyer, E.M. 280, 81
Polli, R., see Murigia, A. 280, 73
Pras, M., see Kaplan, B. 280, 147
Pudil, R., Pidman, V., Krejsek, J., Gregor, J., Tichý, M., Andrýs, C., Drahošová, M., Cytokines and adhesion molecules in the course of acute myocardial infarction 280, 127
Ricós, C., Juvany, R., Simón, M., Hernández, A., Álvarez, V., Jiménez, C.V., Minchinela, J., Perich, C., Commutability and traceability: their repercussions on analytical bias and inaccuracy 280, 135
Rutledge Harding, S., see Lyon, M.E. 280, 91

Salama, G., see Miédougé, M. 280, 161
Serre, G., see Miédougé, M. 280, 161
Simón, M., see Ricós, C. 280, 135
Sumi, S., see Yoshida, K.-i. 280, 195
Suzuki, S., see Yoshida, K.-i. 280, 195

Tichý, M., see Pudil, R. 280, 127
Tsvetkova, I.V., see Beyer, E.M. 280, 81

Udalova, O.V., see Beyer, E.M. 280, 81
van Diggelen, O.P., see Beyer, E.M. 280, 81
Vettor, R., see Federspil, G. 280, 25
Vinzani, C., see Murigia, A. 280, 73
Vincent, C., see Miédougé, M. 280, 161
Vinel, J.-P., see Miédougé, M. 280, 161
Vuust, J., see Larsen, L.A. 280, 113

Waise, A., Clinical audit and the contribution of the laboratory to clinical outcome 280, 47
Wu, A.H.B., Contois, J.H., Cole, T.G., Reflex testing I: Algorithm for lipid and lipoprotein measurement in coronary heart disease risk assessment 280, 181
Yoshida, K.-i., Honda, M., Sumi, S., Arai, K., Suzuki, S., Kitahara, S., Levels of free prostate-specific antigen (PSA) can be selectively measured by heat treatment of serum: free/total-PSA ratios improve detection of prostate carcinoma 280, 195
Yuza, N., see Mitsui, T. 280, 205



ELSEVIER

Clinica Chimica Acta 280 (1999) 213–216



Subject index

Volume 280 (1999)

Acetone; Breadth constituent; Fat metabolism
280, 205

Acridine orange; Lysosomal pH; Storage disease
fibroblasts; Fluorescence microscopy 280, 173

Acute myocardial infarction; Cytokines; Adhe-
sion molecules 280, 127

Adhesion molecules; Acute myocardial infarction;
Cytokines 280, 127

AFP; Alpha-fetoprotein; Ascitic fluid; Albumin;
Hepatocellular carcinoma 280, 161

Albumin; AFP; Alpha-fetoprotein; Ascitic fluid;
Hepatocellular carcinoma 280, 161

Alpha-fetoprotein; AFP; Ascitic fluid; Albumin;
Hepatocellular carcinoma 280, 161

Alzheimer's disease; Amyloid β ; Biochemical
assay; Western blotting 280, 147

Amyloid β ; Alzheimer's disease; Biochemical
assay; Western blotting 280, 147

Anticoagulants; Thrombin inhibitor; Factor Xa
inhibitor; Pre-analytical error; Ionized calcium;
Electrolytes 280, 91

Apolipoproteins; Cholesterol; Triglycerides; Car-
diovascular risk factors; Lp(a) 280, 181

Ascitic fluid; AFP; Alpha-fetoprotein; Albumin;
Hepatocellular carcinoma 280, 161

Athero-thrombotic diseases; Lipoprotein(a); Low
density lipoproteins 280, 59

Bayes'; Theorem; Categorization; Certainty; Cli-
cal methodology; Explanation; Falsification;
Probability 280, 25

Biochemical assay; Alzheimer's disease; Amyloid
 β ; Western blotting 280, 147

Biological variation; Commutability; Traceability
280, 135

Breadth constituent; Acetone; Fat metabolism
280, 205

Cardiovascular risk factors; Cholesterol; Tri-
glycerides; Lp(a); Apolipoproteins 280, 181

Categorization; Bayes'; Theorem; Certainty; Cli-
cal methodology; Explanation; Falsification;
Probability 280, 25

Certainty; Bayes'; Theorem; Categorization; Cli-
cal methodology; Explanation; Falsification;
Probability 280, 25

Choice; Diagnostic tests; Choice management
280, 3

Choice management; Diagnostic tests; Choice
280, 3

Cholesterol; Triglycerides; Cardiovascular risk fac-
tors; Lp(a); Apolipoproteins 280, 181

- Clinical audit;** Inter-laboratory performance; Clinical outcome; Evidence-based medicine **280, 47**
- Clinical audit;** Outcome; Laboratory reasoning; Cost-containment strategies **280, 35**
- Clinical laboratory;** General practitioner; Healthcare; Patient outcomes; Sensitivity; Specificity; Predictive value; Near-patient testing **280, 13**
- Clinical methodology;** Bayes'; Theorem; Categorization; Certainty; Explanation; Falsification; Probability **280, 25**
- Clinical outcome;** Clinical audit; Inter-laboratory performance; Evidence-based medicine **280, 47**
- Commutability;** Traceability; Biological variation **280, 135**
- Cost-containment strategies;** Outcome; Clinical audit; Laboratory reasoning **280, 35**
- Cytokines;** Acute myocardial infarction; Adhesion molecules **280, 127**
- Diagnostic tests;** Choice; Choice management **280, 3**
- Electrolytes;** Thrombin inhibitor; Factor Xa inhibitor; Anticoagulants; Pre-analytical error; Ionized calcium **280, 91**
- Evidence-based medicine;** Clinical audit; Inter-laboratory performance; Clinical outcome **280, 47**
- Explanation;** Bayes'; Theorem; Categorization; Certainty; Clinical methodology; Falsification; Probability **280, 25**
- Fabry disease;** α -Galactosidase; Lysosomal glycosidases; Gene; Mutation **280, 81**
- Factor Xa inhibitor;** Thrombin inhibitor; Anticoagulants; Pre-analytical error; Ionized calcium; Electrolytes **280, 91**
- Falsification;** Bayes'; Theorem; Categorization; Certainty; Clinical methodology; Explanation; Probability **280, 25**
- Fat metabolism;** Acetone; Breadth constituent **280, 205**
- Fluorescence microscopy;** Lysosomal pH; Storage disease fibroblasts; Acridine orange **280, 173**
- Fragile X Syndrome;** Molecular diagnosis; Mutations; VHL **280, 73**
- Free PSA;** Prostate carcinoma; Prostate-specific antigen; Heat treatment **280, 195**
- α -Galactosidase;** Lysosomal glycosidases; Fabry disease; Gene; Mutation **280, 81**
- General practitioner;** Healthcare; Clinical laboratory; Patient outcomes; Sensitivity; Specificity; Predictive value; Near-patient testing **280, 13**
- Gene;** α -Galactosidase; Lysosomal glycosidases; Fabry disease; Mutation **280, 81**
- Healthcare;** General practitioner; Clinical laboratory; Patient outcomes; Sensitivity; Specificity; Predictive value; Near-patient testing **280, 13**
- Heat treatment;** Prostate carcinoma; Prostate-specific antigen; Free PSA **280, 195**
- Hepatocellular carcinoma;** AFP; Alpha-fetoprotein; Ascitic fluid; Albumin **280, 161**
- Heteroduplex analysis;** Long QT syndrome; KVLQT1; Single stranded conformation polymorphism analysis; Mutation detection **280, 113**
- High performance liquid chromatography;** Vitamin B₆ status; Plasma pyridoxal 5'-phosphate; Plasma 4-pyridoxic acid; Older adults; National Diet and Nutrition Survey **280, 101**
- Inter-laboratory performance;** Clinical audit; Clinical outcome; Evidence-based medicine **280, 47**
- Ionized calcium;** Thrombin inhibitor; Factor Xa inhibitor; Anticoagulants; Pre-analytical error; Electrolytes **280, 91**
- KVLQT1;** Long QT syndrome; Single stranded conformation polymorphism analysis; Heteroduplex analysis; Mutation detection **280, 113**
- Laboratory reasoning;** Outcome; Clinical audit; Cost-containment strategies **280, 35**

- Lipoprotein(a);** Low density lipoproteins; Athero-thrombotic diseases **280, 59**
- Long QT syndrome;** KVLQT1; Single stranded conformation polymorphism analysis; Heteroduplex analysis; Mutation detection **280, 113**
- Low density lipoproteins;** Lipoprotein(a); Athero-thrombotic diseases **280, 59**
- Lp(a);** Cholesterol; Triglycerides; Cardiovascular risk factors; Apolipoproteins **280, 181**
- Lysosomal glycosidases;** α -Galactosidase; Fabry disease; Gene; Mutation **280, 81**
- Lysosomal pH;** Storage disease fibroblasts; Fluorescence microscopy; Acridine orange **280, 173**
- Molecular diagnosis;** Mutations; Fragile X Syndrome; VHL **280, 73**
- Mutation;** α -Galactosidase; Lysosomal glycosidases; Fabry disease; Gene **280, 81**
- Mutation detection;** Long QT syndrome; KVLQT1; Single stranded conformation polymorphism analysis; Heteroduplex analysis **280, 113**
- Mutations;** Molecular diagnosis; Fragile X Syndrome; VHL **280, 73**
- National Diet and Nutrition Survey;** Vitamin B₆ status; High performance liquid chromatography; Plasma pyridoxal 5'-phosphate; Plasma 4-pyridoxic acid; Older adults **280, 101**
- Near-patient testing;** General practitioner; Healthcare; Clinical laboratory; Patient outcomes; Sensitivity; Specificity; Predictive value **280, 13**
- Older adults;** Vitamin B₆ status; High performance liquid chromatography; Plasma pyridoxal 5'-phosphate; Plasma 4-pyridoxic acid; National Diet and Nutrition Survey **280, 101**
- Outcome;** Clinical audit; Laboratory reasoning; Cost-containment strategies **280, 35**
- Patient outcomes;** General practitioner; Healthcare; Clinical laboratory; Sensitivity; Specificity; Predictive value; Near-patient testing **280, 13**
- Plasma pyridoxal 5'-phosphate;** Vitamin B₆ status; High performance liquid chromatography; Plasma 4-pyridoxic acid; Older adults; National Diet and Nutrition Survey **280, 101**
- Plasma 4-pyridoxic acid;** Vitamin B₆ status; High performance liquid chromatography; Plasma pyridoxal 5'-phosphate; Older adults; National Diet and Nutrition Survey **280, 101**
- Pre-analytical error;** Thrombin inhibitor; Factor Xa inhibitor; Anticoagulants; Ionized calcium; Electrolytes **280, 91**
- Predictive value;** General practitioner; Healthcare; Clinical laboratory; Patient outcomes; Sensitivity; Specificity; Near-patient testing **280, 13**
- Probability;** Bayes'; Theorem; Categorization; Certainty; Clinical methodology; Explanation; Falsification **280, 25**
- Prostate carcinoma;** Prostate-specific antigen; Free PSA; Heat treatment **280, 195**
- Prostate-specific antigen;** Prostate carcinoma; Free PSA; Heat treatment **280, 195**
- Sensitivity;** General practitioner; Healthcare; Clinical laboratory; Patient outcomes; Specificity; Predictive value; Near-patient testing **280, 13**
- Single stranded conformation polymorphism analysis;** Long QT syndrome; KVLQT1; Heteroduplex analysis; Mutation detection **280, 113**
- Specificity;** General practitioner; Healthcare; Clinical laboratory; Patient outcomes; Sensitivity; Predictive value; Near-patient testing **280, 13**
- Storage disease fibroblasts;** Lysosomal pH; Fluorescence microscopy; Acridine orange **280, 173**
- Theorem;** Bayes'; Categorization; Certainty; Clinical methodology; Explanation; Falsification; Probability **280, 25**
- Thrombin inhibitor;** Factor Xa inhibitor; Anticoagulants; Pre-analytical error; Ionized calcium; Electrolytes **280, 91**
- Traceability;** Commutability; Biological variation **280, 135**

Triglycerides; Cholesterol; Cardiovascular risk factors; Lp(a); Apolipoproteins **280**, 181

VHL; Molecular diagnosis; Mutations; Fragile X Syndrome **280**, 73

Vitamin B₆ status; High performance liquid chro-

matography; Plasma pyridoxal 5'-phosphate; Plasma 4-pyridoxic acid; Older adults; National Diet and Nutrition Survey **280**, 101

Western blotting; Alzheimer's disease; Amyloid β ; Biochemical assay **280**, 147

